Data updated: Mar 29, 2026

IMMUNEX

Oncology

Biotech

IMMUNEX is a biotechnology company focused on Oncology.

1959

Since

4

Drugs

-

Trials

9

Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Recent Activity

ENBREL 2026-01-30

ENBREL 2025-12-10

ENBREL 2025-06-18

ENBREL 2024-09-12

THIOTEPA 2024-08-20

ENBREL 2024-07-22

ENBREL 2024-07-22

ENBREL 2024-07-22

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 100%

1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma

Novartis big-pharma

Merck big-pharma

Baxter specialty

AbbVie big-pharma